Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer.

Trial Profile

Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Tasquinimod (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Active Biotech Research
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Jun 2013 Retrospective follow-up data was presented at the 2013 ASCO Annual Meeting, according to an Active Biotech media release.
    • 16 May 2013 Data will be presented at the 2013 ASCO Annual Meeting, according to an Active Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top